Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
chronic toxicity: oral
Type of information:
experimental study
Adequacy of study:
supporting study
Reliability:
4 (not assignable)
Rationale for reliability incl. deficiencies:
abstract
Justification for type of information:
A scientific review.

Data source

Referenceopen allclose all

Reference Type:
review article or handbook
Title:
Final Report on the Safety Assessment of Sodium Metaphosphate, Sodium Trimetaphosphate, and Sodium Hexametaphosphate
Author:
Reviewed by the Cosmetic Ingredient Review Expert Panel.
Year:
2001
Bibliographic source:
International Journal of Toxicology, p 75-89.
Reference Type:
review article or handbook
Title:
Summaries of toxicological data: Toxicity studies on phosphates .
Year:
1964
Bibliographic source:
Food Cosmet. Toxicol. 2:147–154.

Materials and methods

Principles of method if other than guideline:
No information on the method. Male and female weanling rats (50 per group) were fed basal diet plus 0.05%, 0.5%, or 5.0% Sodium Hexametaphosphate.
GLP compliance:
not specified
Limit test:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
Sodium metaphosphate
EC Number:
233-343-1
EC Name:
Sodium metaphosphate
Cas Number:
10124-56-8
Molecular formula:
Na6O18P6
IUPAC Name:
hexasodium 2,4,6,8,10,12-hexaoxocyclohexaphosphoxane-2,4,6,8,10,12-hexakis(olate)

Test animals

Species:
rat
Sex:
male/female

Administration / exposure

Route of administration:
oral: feed
No. of animals per sex per dose:
50

Results and discussion

Results of examinations

Clinical signs:
effects observed, treatment-related
Description (incidence and severity):
Rats fed 0.5% to 5.0% Sodium Hexametaphosphate had increased kidney to body weight ratios. Renal infections were observed more frequently in rats of groups given Sodium Hexametaphosphate than in rats of the control group. Female rats of the high-dose group had “possibly increased” lung weights and decreased splenic weights. The incidence of renal infection made diffcult the interpretation of organ weights.
One female rat fed 0.5% Sodium Hexametaphosphate, and 13 of 20 rats given 5.0% Sodium Hexametaphosphate had calcination of the renal tubules.
Mortality:
mortality observed, treatment-related
Description (incidence):
A dose-related increase in mortality was not observed during the test period; however, overall mortality was 64% to 78% (females surviving better than males). The median life span was greatest in males given the medium dose of Sodium Hexametaphosphate. The most common cause of death was respiratory infection.
Body weight and weight changes:
no effects observed
Description (incidence and severity):
Rats of the control group had no observed effects on growth. Of rats given the low and median doses of Sodium Hexametaphosphate, no adverse effect swere noted.
Males of the high-dose group had reduced growth, but females of the same group were only slightly affected. Rats of the high-dose group had greater feed consumption at days 90 and 210, as compared to rats of the control group.
Food consumption and compound intake (if feeding study):
not specified
Food efficiency:
not specified
Water consumption and compound intake (if drinking water study):
not specified
Ophthalmological findings:
not specified
Haematological findings:
no effects observed
Description (incidence and severity):
Hematologic parameters did not differ from those of controls.
Clinical biochemistry findings:
not specified
Urinalysis findings:
no effects observed
Description (incidence and severity):
Only traces of protein and reducing substances were found in the urine.
Behaviour (functional findings):
not specified
Immunological findings:
not specified
Organ weight findings including organ / body weight ratios:
effects observed, treatment-related
Description (incidence and severity):
Rats fed 0.5% to 5.0% Sodium Hexametaphosphate had increased kidney to body weight ratios. Renal infections were observed more frequently in rats of groups given Sodium Hexametaphosphate than in rats of the control group. Female rats of the high-dose group had “possibly increased” lung weights and decreased splenic weights. The incidence of renal infection made diffcult the interpretation of organ weights.
Gross pathological findings:
not specified
Neuropathological findings:
not specified
Histopathological findings: non-neoplastic:
not specified
Histopathological findings: neoplastic:
not specified
Other effects:
effects observed, treatment-related
Description (incidence and severity):
The femur lengths were not significantly affected by treatment with Sodium Hexametaphosphate. The femurs of all rats had comparable water, ash, calcium, and phosphorus contents, and appeared normal in radiograph.

Applicant's summary and conclusion

Conclusions:
No adverse effects were noted at male and female rats given the low and median doses (0.05 and 0.5%) of Sodium Hexametaphosphate (2 years study).
Executive summary:

No adverse effects were noted at male and female rats given the low and median doses (0.05 and 0.5%) of Sodium Hexametaphosphate (2 years study).

A dose-related increase in mortality was not observed during the test period; however, overall mortality was 64% to 78% (females surviving better than males). The median life span was greatest in males given the medium dose of Sodium Hexametaphosphate.